Company: NDRA
Filing Date: 2025-03-31
Form Type: 10-K
Source: 0001654954-25-003612
Chunk: 654

Company: ENDRA Life Sciences Inc.
Filing Date: 2025-03-31
Form: 10-K
Item: Item 5
Chunk 654
---
-9 

During the year ended December 31, 2024, the Company issued a total of 530,971 shares of its common stock, as follows:  Registered offering (described below): ·3,490 shares of its common stock in return for aggregate net proceeds of $728,503 under the Placement Agreement; ·31,666 shares of its common stock upon exercise of pre-funded warrants for aggregate net proceeds of $6,609,831 under the Placement Agreement (includes net proceeds from sale and exercise of pre-funded warrants);   Other issuances: ·68 shares of its common stock upon warrant exercises for aggregate net proceeds of $77,419; ·181 shares of its common stock in return for aggregate net proceeds of $419,967 under the June 2021 ATM Agreement; ·5 shares of its common stock upon conversion of 123.909 shares of its Series A Preferred Stock; and ·46 shares of the previously issued restricted common stock vested. The shares were issued for services and valued at $80,000. ·39 shares of common stock issued as beneficial round up shares as a result of our reverse stock splits   Series B warrant exercises: ·495,476 shares of its common stock upon cashless exercise of Series B Warrants  During the year ended December 31, 2023, the Company issued a total of 4,126 shares of its common stock, as follows:  ·2,464 shares of its common stock in return for aggregate net proceeds of $4,712,750 in a registered underwritten offering that closed on May 2, 2023; ·757 shares of its common stock in return for aggregate net proceeds of $1,770,643 under the June 2021 ATM Agreement; ·905 upon warrant exercises for an aggregate net proceeds of $1,014,859.   Registered Offering On June 4, 2024, the Company entered into a placement agency agreement (the “Placement Agreement”) with Craig-Hallum Capital Group LLC (the “Placement Agent”) pursuant to which the Placement Agent served, on a best efforts basis, in connection with the issuance and sale (the “Offering”) of 3,490 shares of common stock and 31,674 pre-funded warrants to purchase up to an aggregate of 31,666 shares of common stock (the “pre-funded warrants”), together with Series A warrants to purchase up to an aggregate of 178,255